Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 53 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR New analysis estimates over 21 million UK adults will be obese... May 18, 2022 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 Altering Diet Enhances Response to Cancer Treatments in Mice September 3, 2019 How can we improve LGBTQ+ cancer care? – That Cancer Conversation... June 27, 2023 Load more HOT NEWS Could Cholesterol-Lowering Drugs Improve Cancer Immunotherapy? Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer ‘Hamilton’ Star Who Battled Breast Cancer is Giving Back to Current...
